Cutting edge: IL-12 and type I IFN differentially program CD8 T cells for programmed death 1 re-expression levels and tumor control.

Gerner, Michael Y; Heltemes-Harris, Lynn M; Fife, Brian T; Mescher, Matthew F

Gerner, Michael Y; Heltemes-Harris, Lynn M; Fife, Brian T; Mescher, Matthew F.

Affiliation

Gerner MY; Department of Laboratory Medicine and Pathology, Center for Immunology, University of Minnesota, Minneapolis, MN 55455, USA.

J Immunol ; 191(3): 1011-5, 2013 Aug 01.

Article in En | MEDLINE | ID: mdl-23804712

Subject(s)

CD8-Positive T-Lymphocytes/immunology; Interferon Type I/metabolism; Interferon-alpha/metabolism; Interleukin-12/metabolism; Programmed Cell Death 1 Receptor/metabolism; Animals; Antibodies, Monoclonal/immunology; B7-H1 Antigen/immunology; B7-H1 Antigen/metabolism; Cell Proliferation; Lymphocyte Activation/immunology; Mice; Neoplasms/immunology; Programmed Cell Death 1 Receptor/biosynthesis; Signal Transduction/immunology; T-Lymphocytes, Cytotoxic/immunology

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Interferon Type I / Interferon-alpha / Interleukin-12 / CD8-Positive T-Lymphocytes / Programmed Cell Death 1 Receptor Type of study: Prognostic_studies Limits: Animals Language: En Journal: J Immunol Year: 2013 Document type: Article Affiliation country: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google